Latest news from Rakuten Medical, Inc. on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/rakuten-medical-announce-over-20-presentations-on-alluminox-treatment-photoimmunotherapy-at-international-conferences-in-2023/?sc=rsin /articles/rakuten-medical-announce-over-20-presentations-on-alluminox-treatment-photoimmunotherapy-at-international-conferences-in-2023/?sc=rsin Fri, 01 Mar 2024 09:00:09 EST Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox(tm) platform, is pleased to announce that, during the year 2023, findings from preclinical studies, clinical trials, and real-world data on Alluminox treatment (photoimmunotherapy) have been presented at multiple international conferences. The 21 presentations are listed at the end of the press release. Rakuten Medical, Inc. /articles/rakuten-medical-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-january-10th-2024/?sc=rsin /articles/rakuten-medical-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference-on-january-10th-2024/?sc=rsin Thu, 14 Dec 2023 07:05:23 EST Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy treatments based on its proprietary Alluminox(tm) platform, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024. Rakuten Medical, Inc. /articles/rakuten-medical-presents-ai-based-study-in-two-posters-on-immune-characteristics-in-responders-and-cellular-level-drug-quantification-of-alluminox-treatment-photoimmunotherapy-at-sitc-2023/?sc=rsin /articles/rakuten-medical-presents-ai-based-study-in-two-posters-on-immune-characteristics-in-responders-and-cellular-level-drug-quantification-of-alluminox-treatment-photoimmunotherapy-at-sitc-2023/?sc=rsin Mon, 06 Nov 2023 18:05:02 EST Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeted therapies based on its proprietary Alluminox(tm) platform today announced the presentation of two posters of AI-based analyses at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 3-5, 2023, in San Diego, CA (SITC 2023). Rakuten Medical, Inc. /articles/rakuten-medical-to-present-at-2023-jefferies-london-healthcare-conference-on-november-14/?sc=rsin /articles/rakuten-medical-to-present-at-2023-jefferies-london-healthcare-conference-on-november-14/?sc=rsin Thu, 02 Nov 2023 20:05:46 EST Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox(tm) platform, today announced that the Company will present at the 14th Annual Jefferies London Healthcare Conference being held in London, UK, on November 14-16, 2023. Rakuten Medical, Inc. /articles/rakuten-medical-and-hikma-sign-exclusive-licensing-agreement-for-alluminox-platform-cancer-treatment-in-the-middle-east-and-north-africa/?sc=rsin /articles/rakuten-medical-and-hikma-sign-exclusive-licensing-agreement-for-alluminox-platform-cancer-treatment-in-the-middle-east-and-north-africa/?sc=rsin Thu, 10 Aug 2023 08:05:52 EST Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox(tm) platform today announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA). Rakuten Medical, Inc. /articles/rakuten-medical-to-host-virtual-rd-day-on-thursday-august-10-2023/?sc=rsin /articles/rakuten-medical-to-host-virtual-rd-day-on-thursday-august-10-2023/?sc=rsin Tue, 18 Jul 2023 08:50:07 EST Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy-based on its proprietary Alluminox(tm) platform, today announced it will host a virtual R&D Day on the preliminary safety and efficacy findings from its open-label Phase 1b/2 study of Alluminox(tm) treatment using ASP-1929 in combination with anti-PD-1 therapy in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Rakuten Medical, Inc. /articles/first-safety-and-efficacy-data-of-rakuten-medical-s-alluminox-treatment-using-asp-1929-in-combination-with-anti-pd-1-for-recurrent-andor-metastatic-head-and-neck-cancer-presented-at-ahns-2023/?sc=rsin /articles/first-safety-and-efficacy-data-of-rakuten-medical-s-alluminox-treatment-using-asp-1929-in-combination-with-anti-pd-1-for-recurrent-andor-metastatic-head-and-neck-cancer-presented-at-ahns-2023/?sc=rsin Mon, 10 Jul 2023 16:05:39 EST Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox(tm) platform, today announced that new data from the ASP-1929-181 study was presented at the American Head and Neck Society's (AHNS) 11th International Conference on Head and Neck Cancer (AHNS 2023) on July 10, 2023. Rakuten Medical, Inc. /articles/new-preliminary-findings-on-potential-response-indicator-of-rakuten-medical-s-alluminox-treatment-from-phase-2-window-of-opportunity-study-at-snmmi-2023/?sc=rsin /articles/new-preliminary-findings-on-potential-response-indicator-of-rakuten-medical-s-alluminox-treatment-from-phase-2-window-of-opportunity-study-at-snmmi-2023/?sc=rsin Fri, 30 Jun 2023 14:20:04 EST Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox(tm) platform, today announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting held from June 24 to 27. Rakuten Medical, Inc. /articles/rakuten-medical-presents-data-characterizing-how-photoimmunotherapy-induces-cancer-cell-death-and-enhances-the-immune-response-preclinically/?sc=rsin /articles/rakuten-medical-presents-data-characterizing-how-photoimmunotherapy-induces-cancer-cell-death-and-enhances-the-immune-response-preclinically/?sc=rsin Mon, 22 Jun 2020 09:50:14 EST Studies Presented at the American Association for Cancer Research Virtual Meeting II Rakuten Medical, Inc. /articles/rakuten-medical-and-md-anderson-announce-strategic-alliance-to-advance-illuminox-platform-for-cancer-treatments/?sc=rsin /articles/rakuten-medical-and-md-anderson-announce-strategic-alliance-to-advance-illuminox-platform-for-cancer-treatments/?sc=rsin Thu, 04 Jun 2020 09:00:06 EST Rakuten Medical, Inc. (Rakuten Medical) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical's proprietary Illuminox(tm) technology platform. Rakuten Medical, Inc.